Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study

Paul M McKeigue, David A McAllister, Chris Robertson, Sharon Hutchinson, Stuart McGurnaghan, Diane Stockton, Helen M Colhoun, for the PHS COVID-19 Epidemiology and Research Cell
doi: https://doi.org/10.1101/2021.09.13.21262360

Article usage

Article usage: September 2021 to June 2025

AbstractFullPdf
Sep 2021190265331
Oct 202158625130
Nov 20214492282
Dec 20211871225
Jan 2022881013
Feb 2022107139
Mar 2022911815
Apr 2022841316
May 202277617
Jun 2022104515
Jul 20224918
Aug 20225048
Sep 202273213
Oct 20226318
Nov 20224445
Dec 20223729
Jan 202347111
Feb 202345510
Mar 20233912
Apr 20233225
May 20233419
Jun 20232464
Jul 20232115
Aug 20233199
Sep 20232855
Oct 20231803
Nov 20233487
Dec 20231534
Jan 20242006
Feb 20241629
Mar 20241827
Apr 2024251114
May 20241543
Jun 202417610
Jul 20242206
Aug 202431912
Sep 20243089
Oct 20241014
Nov 2024221016
Dec 20241719
Jan 20252126
Feb 2025162011
Mar 2025523818
Apr 202523115
May 202522615
Jun 2025511
Back to top
Posted October 28, 2021.
Download PDF
Data/Code
Email
Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study
Paul M McKeigue, David A McAllister, Chris Robertson, Sharon Hutchinson, Stuart McGurnaghan, Diane Stockton, Helen M Colhoun, for the PHS COVID-19 Epidemiology and Research Cell
medRxiv 2021.09.13.21262360; doi: https://doi.org/10.1101/2021.09.13.21262360
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area